/LQDA
LQDA Stock - Liquidia Corporation
Healthcare|BiotechnologyNASDAQ
$34.53+2.55%
+$0.86 (+2.55%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+37.1%upside
Target: $47.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LQDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$34.18 – $34.88
TARGET (TP)$47.33
STOP LOSS$31.77
RISK/REWARD1:4.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$35.54
52W Low$10.96
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M | $739,628 |
| Gross Profit | $8.12M | $14.60M | $13.08M | $9.83M | $501,916 |
| Gross Margin | 58.0% | 83.5% | 82.1% | 76.5% | 67.9% |
| Operating Income | $-121,294,000 | $-73,384,000 | $-38,770,000 | $-33,797,000 | $-59,089,130 |
| Net Income | $-130,394,000 | $-78,502,000 | $-41,015,000 | $-34,579,000 | $-59,762,769 |
| Net Margin | -931.7% | -448.9% | -257.4% | -269.0% | -8080.1% |
| EPS | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 |
Company Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
1
9%
Buy / Outperform
7
64%
Hold / Neutral
0%
Sell / Underperform
3
27%
Analyst Consensus🟢 Bullish
8 Bullish3 Neutral/Bearish
Price Targets
$19
Average Target
↓ 45.0% Downside
Now
$3
Low
$19
Average
$43
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $31 |
| August 15th 2025 | Jefferies | Resumed | Buy | $43 |
| May 19th 2025 | Oppenheimer | Downgrade | Underperform | $13 |
| December 20th 2024 | Wells Fargo | Initiation | Overweight | $20 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| August 19th 2024 | Raymond James | Upgrade | Strong Buy | - |
| August 16th 2024 | Raymond James | Initiation | Outperform | $27 |
| June 25th 2024 | Oppenheimer | Initiation | Perform | - |
| January 5th 2024 | Needham | Reiterated | Buy | $28← $18 |
| September 19th 2022 | Wedbush | Resumed | Underperform | $3 |
| September 1st 2022 | Wedbush | Downgrade | Underperform | $3 |
| July 22nd 2022 | Ladenburg Thalmann | Initiation | Buy | $15 |
| May 31st 2022 | BTIG Research | Initiation | Buy | $14 |
| May 26th 2022 | BofA Securities | Initiation | Buy | $12 |
Earnings History & Surprises
LQDABeat Rate
28%
Last 18 quarters
Avg Surprise
-16.1%
EPS vs Estimate
Beats / Misses
5/11
2 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
-82.6%
$-0.42vs$-0.23
Q2 24
-68.8%
$-0.54vs$-0.32
Q3 24
-5.7%
$-0.37vs$-0.35
Q4 24
0.0%
$-0.37vs$-0.37
Q1 25
-21.1%
$-0.46vs$-0.38
Q2 25
-7.1%
$-0.45vs$-0.42
Q3 25
-14.0%
$-0.49vs$-0.43
Q4 25
+91.1%
$-0.04vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $0.08 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.45 | $-0.04 | +91.1% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.43 | $-0.49 | -14.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q1 2025 | Mar 19, 2025 | $-0.38 | $-0.46 | -21.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.37 | $-0.37 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.32 | $-0.54 | -68.8% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.23 | $-0.42 | -82.6% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.17 | $-0.36 | -111.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2023 | Mar 16, 2023 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.11 | $-0.23 | -109.1% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $50
📈 PositiveBenzinga•Nov 4, 2025, 05:24 PM
Liquidia shares are trading higher after Needham raised its price target on the stock from $36 to $52.
📈 PositiveBenzinga•Nov 4, 2025, 04:04 PM
Needham Maintains Buy on Liquidia, Raises Price Target to $52
📈 PositiveBenzinga•Nov 4, 2025, 10:36 AM
BTIG Reiterates Buy on Liquidia, Maintains $49 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 10:32 AM
LQDA stock has given up its prior gain. Liquidia shares were trading higher after the company reported better-than-expected Q3 financial results
➖ NeutralBenzinga•Nov 3, 2025, 02:55 PM
Liquidia shares are trading higher after the company reported better-than-expected Q3 financial results
📈 PositiveBenzinga•Nov 3, 2025, 01:40 PM
Liquidia Q3 EPS $(0.04) Beats $(0.40) Estimate, Sales $54.342M Beat $18.825M Estimate
📈 PositiveBenzinga•Nov 3, 2025, 11:31 AM
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $35 Price Target
📈 PositiveBenzinga•Oct 6, 2025, 10:39 AM
Liquidia To Present Clinical Data From ASCENT Trial At CHEST 2025 Annual Meeting Oct. 21
➖ NeutralBenzinga•Sep 29, 2025, 01:23 PM
Liquidia To Present New LIQ861 Data From ASCENT Trial At CHEST 2025 Annual Meeting
📈 PositiveBenzinga•Sep 29, 2025, 01:21 PM
Liquidia, United Therapeutics fall after mid-stage data for Insmed's PAH asset
📉 NegativeSeeking Alpha•Jun 10, 2025, 11:58 AM•Also: ,
Liquidia surges 15% as court clears way for Yutrepia launch
📈 PositiveSeeking Alpha•May 2, 2025, 06:50 PM
Frequently Asked Questions about LQDA
What is LQDA's current stock price?
Liquidia Corporation (LQDA) is currently trading at $34.53 per share. The stock has moved +2.55% today.
What is the analyst price target for LQDA?
The average analyst price target for LQDA is $47.33, based on 1 analyst.
What sector is Liquidia Corporation in?
Liquidia Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LQDA's market cap?
Liquidia Corporation has a market capitalization of $2.95 billion, making it a mid-cap company.
Does LQDA pay dividends?
No, Liquidia Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
Explore stocks similar to LQDA for comparison